“…Some States in the US have shifted their policy stance to permit use of cannabis for therapeutic purposes (CTP) (Chu, 2014). This legalisation in the form of de facto supply for medical use has not caused increased consumption, prevalence of use or related adverse consequences (Nussbaum, Boyer & Kondrad, 2011;Hall & Weier, 2015;Sznitman and Zolotov, 2015;Ziemianski, Capler, Tekanoff , Lacasse, Luconi & Ware, 2015) and according to one study has contributed to heightened patient perceptions of safety and awareness (Trout & DiDonato, 2015). (Ebert, Zolotov, Eliav, Ginzburg, Shapira & Magnezi, 2015), with Israeli rheumatologists observing a majority opinion for the role of cannabinoids in the management of rheumatoid disease (Ablin, Elkayam & Fitzcharles, 2016).…”